


Candida + IBS Profile

At Home Blood DBS

Key Clinical Messages



What is the Candida + IBS Profile?

The Candida + IBS Profile is a blood-based panel that assesses fungal overgrowth, immune responses linked to irritable bowel syndrome (IBS), and autoimmune-related disruptions to intestinal motility.

- Detects IgM and pooled IgG + IgA antibodies to 11 fungal species and 2 key IBS markers (vinculin and CdtB).
- Links hidden fungal colonization or post-infectious gut autoimmunity to chronic gastrointestinal and systemic symptoms.

Provides a systemic view of fungal sensitivity and post-infectious IBS subtypes, guiding personalized protocols to reduce inflammation and restore gut motility.



11 Fungal Antibody Panel

2 Post-Infectious IBS Antibodies



Why Order?

The Candida + IBS Profile is ideal for patients with persistent gut symptoms despite negative stool testing or antimicrobial therapy. It offers deeper insight into "stealth" fungal activity, gut-immune interactions, and post-gastroenteritis autoimmunity. This makes it especially useful in cases of suspected fungal overgrowth, IBS-D, IBS-M, or recurring GI symptoms without clear microbial cause.




[Download Sample Report](#)

Synergistic Testing Options

- **Gut Zoomer:** Offers direct detection of *Candida* DNA and provides stool-based context for the antibody findings. Also evaluates microbiome balance, inflammation, permeability, and beta-glucuronidase, all of which influence fungal proliferation and persistence.
- **Mycotoxins:** Mold toxins can weaken immune responses and alter the gut environment, creating favorable conditions for fungal colonization. This test clarifies whether symptoms stem from fungal growth, environmental mycotoxins, or both.
- **Environmental Toxins or Heavy Metals:** Toxins like parabens, phthalates, and metals may suppress antifungal immunity or damage the gut lining, increasing vulnerability to overgrowth. Pairing helps determine if chemical exposures are driving fungal or IBS symptoms.
- **Organic Acids:** Identifies fungal metabolic byproducts (like arabinose) and coexisting patterns of oxidative stress or mitochondrial dysfunction. This test translates antibody results into actionable insights on fungal impact at the metabolic level.

The Vibrant Advantage

- **Dual IBS-Autoimmunity Biomarkers:** Measures IgG antibodies to CdtB (to detect post-infectious gastroenteritis) and vinculin (to identify IBS-D and IBS-M subtypes).
- **Comprehensive Fungal Panel:** Includes 8 *Candida* species plus *Trichosporon*, *Cladosporium*, and *Saccharomyces cerevisiae* for full-spectrum fungal sensitivity assessment.
- **Antibody-Based Fungal Detection:** Identifies immune responses to fungal colonization even when stool PCR or culture tests return negative, ideal for uncovering stealth or biofilm-associated species missed by direct testing.
- **Microarray Precision:** Uses chemiluminescence microarray for high specificity and reproducibility in measuring low-abundance antibodies.



Additional Resources



Markers One-Sheet



Patient One-Pager



Interpretive Guide



Report Walkthrough



Limitations

Please note the information provided by Vibrant Wellness is intended solely for research and informational purposes to help inform lifestyle choices aimed at potential risk mitigation. The information is not intended to be used by the patient for any diagnostic purpose and is not a substitute for medical advice by a healthcare practitioner. Please consult a licensed healthcare practitioner for any questions regarding diagnosis, prevention, or treatment of any disease or health assessment.

Regulatory Disclaimer

Please note the information provided by Vibrant Wellness is intended solely for research and informational purposes to help inform lifestyle choices aimed at potential risk mitigation. The tests were developed, and their performance characteristics were determined by Vibrant America and Vibrant Genomics. They have not been cleared or approved by US Food and Drug Administration. The laboratory is certified under the Clinical Laboratory Improvements Amendments (CLIA) as qualified to perform high complexity testing. The laboratory is also in compliance with College of American Pathologists (CAP) regulations and New York State Department of Health (NYSDOH) regulations.

KCM-25-016